organization · Reporting owner
Topspin Biotech Fund II, L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 23, 2018 · Filed July 23, 2018
Jointly reported with Topspin Fund L.P., LG Management, LLC, GUTHART LEO
Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 445,270 |
Reported balance
After 2018-07-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-23 · Conversion · Acquired 445,270 · Balance 445,270 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Funds | 1,277,984 |
Reported balance
After 2018-07-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-07-23 · Conversion · Acquired 1,277,984 · Balance 1,277,984 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Common StockSEC Table I · non-derivative | IndirectBy MSSB C/F Leo A. Guthart | 54,770 |
Reported balance
After 2018-07-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-07-23 · Conversion · Acquired 54,770 · Balance 54,770 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-23 · Conversion · Disposed 177,777 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Series E-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-23 · Conversion · Disposed 173,408 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Series F Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-07-23 · Conversion · Disposed 4,500,000 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2018-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-07-23 · Conversion · Disposed 6,222,222 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Series E-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Funds | 0 |
Reported balance
After 2018-07-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-07-23 · Conversion · Disposed 6,069,332 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy MSSB C/F Leo A. Guthart | 0 |
Reported balance
After 2018-07-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-07-23 · Conversion · Disposed 266,667 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. |
| Series E-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy MSSB C/F Leo A. Guthart | 0 |
Reported balance
After 2018-07-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-07-23 · Conversion · Disposed 260,114 · Balance 0 F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
F2: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
F3: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
F4: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares.
Oric Pharmaceuticals, Inc.
Report date November 04, 2020 · Filed November 05, 2020
Jointly reported with Topspin Fund L.P., LG Management, LLC, GUTHART LEO
Section 16 reporting ended · disclosed 2020-11-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,100,446 |
Reported balance
After 2020-11-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-04 · Sale · Disposed 2,268,750 · Balance 1,100,446 F2: On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F1: Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. F3: 1,043,874 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other.
F2: On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P.
F3: 1,043,874 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
RAPT Therapeutics, Inc.
Report date May 26, 2020 · Filed May 29, 2020
Jointly reported with Topspin Fund L.P., LG Management, LLC, GUTHART LEO
Section 16 reporting ended · disclosed 2020-05-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFootnote | 559,243 |
Reported balance
After 2020-05-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-05-26 · Sale · Disposed 2,056,666 · Balance 559,243 F2: On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F3: On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners. F1: Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. F4: 518,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other.
F2: On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P.
F3: On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners.
F4: 518,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2020 Filed Nov 5, 2020 08:56 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,268,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-121613 · tm2035065-2_4.xml · nonDerivative · entry 1 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,100,446 F2 · price: On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F1 · balance_after: Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. F2 · balance_after: On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F3 · balance_after: 1,043,874 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. F1 · ownership.nature: Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP.; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. Read SEC document |
| May 26, 2020 Filed May 29, 2020 12:21 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | SaleCommon Stock | 2,056,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-067505 · tm2021084-1_4.xml · nonDerivative · entry 1 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 559,243 F2 · price: On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F3 · price: On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners. F1 · balance_after: Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. F2 · balance_after: On May 26, 2020, Topspin Biotech Fund II, L.P. distributed the 1,641,666 shares owned by it as follows: (1) 1,559,990 shares were distributed in-kind to its limited partners; and (2) 81,676 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 40,538 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 41,138 were distributed to two third-parties. The 81,676 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P. F3 · balance_after: On May 26, 2020, Topspin Fund, L.P. distributed 415,000 shares owned by it to one of its limited partners. F4 · balance_after: 518,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. F1 · ownership.nature: Consists of (1) 518,705 shares held of record by Topspin Fund, LP.; and (2) 40,538 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of recod by the other. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionSeries B Preferred Stock · Derivative | 2,268,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · derivative · entry 8 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,268,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F3 · ownership.nature: The shares are held of record by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionSeries D Preferred Stock · Derivative | 314,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · derivative · entry 7 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 314,815 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionSeries C Preferred Stock · Derivative | 497,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · derivative · entry 6 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 497,809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionSeries B Preferred Stock · Derivative | 231,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · derivative · entry 5 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 231,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionCommon Stock | 2,268,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · nonDerivative · entry 4 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,268,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F3 · ownership.nature: The shares are held of record by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionCommon Stock | 314,815 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · nonDerivative · entry 3 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionCommon Stock | 497,809 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · nonDerivative · entry 2 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| April 28, 2020 Filed Apr 28, 2020 17:11 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | ConversionCommon Stock | 231,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025989 · doc4.xml · nonDerivative · entry 1 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. F2 · ownership.direct: The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| November 04, 2019 Filed Nov 15, 2019 14:52 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | ConversionSeries C-2 Preferred Stock · Derivative | 155,201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-064691 · tv532611_4.xml · derivative · entry 4 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · derivative.expiration_date: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. Read SEC document |
| November 04, 2019 Filed Nov 15, 2019 14:52 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | ConversionSeries C Preferred Stock · Derivative | 363,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-064691 · tv532611_4.xml · derivative · entry 3 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 363,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · derivative.expiration_date: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. Read SEC document |
| November 04, 2019 Filed Nov 15, 2019 14:52 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | ConversionSeries B Preferred Stock · Derivative | 1,641,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-064691 · tv532611_4.xml · derivative · entry 2 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes 2, 3 and 4 Disclosed balance after: 0 Underlying: Common Stock · 1,641,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · price: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. F2 · derivative.expiration_date: Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above. Read SEC document |
| November 04, 2019 Filed Nov 15, 2019 14:52 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | PurchaseCommon Stock | 415,000 | $12.00 | $4,980,000.00 |
DisclosureSEC source: 0001104659-19-064691 · tv532611_4.xml · nonDerivative · entry 1 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,575,371 F1 · balance_after: Consists of (1) 1,641,666 shares held of record by Topspin Biotech Fund II, LP; and (ii) 933,705 shares held of record by Topspin Fund, LP. Each of Topspin Biotech Fund II, LP and Topspin Fund, LP disclaims beneficial ownership of the shares held of record by the other. F3 · balance_after: 1,641,666 of such shares are held directly by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. F4 · balance_after: 933,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. F1 · ownership.nature: Consists of (1) 1,641,666 shares held of record by Topspin Biotech Fund II, LP; and (ii) 933,705 shares held of record by Topspin Fund, LP. Each of Topspin Biotech Fund II, LP and Topspin Fund, LP disclaims beneficial ownership of the shares held of record by the other. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E-1 Preferred Stock · Derivative | 260,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 10 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By MSSB C/F Leo A. Guthart Disclosed balance after: 0 Underlying: Common Stock · 23,627 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4 · ownership.direct: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E Preferred Stock · Derivative | 266,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 9 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By MSSB C/F Leo A. Guthart Disclosed balance after: 0 Underlying: Common Stock · 31,143 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4 · ownership.direct: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E-1 Preferred Stock · Derivative | 6,069,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 8 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 551,306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3 · ownership.direct: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E Preferred Stock · Derivative | 6,222,222 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 7 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 0 Underlying: Common Stock · 726,678 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3 · ownership.direct: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries F Preferred Stock · Derivative | 4,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 6 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 408,758 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E-1 Preferred Stock · Derivative | 173,408 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 5 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E Preferred Stock · Derivative | 177,777 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · derivative · entry 4 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,762 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionCommon Stock | 54,770 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · nonDerivative · entry 3 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By MSSB C/F Leo A. Guthart Disclosed balance after: 54,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F4 · ownership.direct: The securities are held directly by individual retirement accounts in the name of Leo A. Guthart and as a result Leo A Guthart may be deemed to be the beneficial owner of such shares. Leo A. Guthart disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionCommon Stock | 1,277,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · nonDerivative · entry 2 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Funds Disclosed balance after: 1,277,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F3 · ownership.direct: The securities are directly held by Topspin Biotech Fund L.P. LG Management, LLC, the general partner of Topspin Biotech Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:07 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionCommon Stock | 445,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-020453 · doc4.xml · nonDerivative · entry 1 Topspin Fund L.P. · CIK 0001615782 · 10% owner Topspin Biotech Fund II, L.P. · CIK 0001745827 · 10% owner LG Management, LLC · CIK 0001685869 · 10% owner GUTHART LEO · CIK 0001200183 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 23, 2018, the Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: The securities are directly held by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.